This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/bindingdb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/chemspider/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/ontology/mesh/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/chebi/
n18http://www.rxlist.com/cgi/generic2/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00892/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00892
rdf:type
n10:Drug
n10:description
Oxybuprocaine is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.
n10:group
approved
n10:indication
Used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.
n10:manufacturer
n14:271B5964-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00892 n19:DB00892
dcterms:title
Oxybuprocaine
adms:identifier
n4:PA164764617 n5:Oxybuprocaine n20:4633 n21:46505399 n22:D01768 n23:4472 n24:DB00892 n25:50017709 n26:309594
n10:mechanismOfAction
Oxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.
n10:packager
n14:271B5963-363D-11E5-9242-09173F13E4C5
n10:synonym
Benoxil Oxyriprocaine BNX Oxybuprocainum 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester Oxybucaine 4-Amino-3-N-butoxy-benzoesaeure-diaethylaminoaethylester Benoxinate Oxibuprocaina Butoxyaminobenzoyldiethylaminoethanol 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid
n10:mixture
n16:271B5962-363D-11E5-9242-09173F13E4C5
n10:salt
n10:synthesisReference
Katsuyuki Inoo, Mitsuhiro Kawada, Kenjiro Mori, "Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation." U.S. Patent US20110124727, issued May 26, 2011.
n6:hasConcept
n7:M0046757
foaf:page
n18:fluress.htm
n10:IUPAC-Name
n13:271B596A-363D-11E5-9242-09173F13E4C5
n10:InChI
n13:271B5970-363D-11E5-9242-09173F13E4C5
n10:Molecular-Formula
n13:271B596F-363D-11E5-9242-09173F13E4C5
n10:Molecular-Weight
n13:271B596C-363D-11E5-9242-09173F13E4C5
n10:Monoisotopic-Weight
n13:271B596D-363D-11E5-9242-09173F13E4C5
n10:SMILES
n13:271B596E-363D-11E5-9242-09173F13E4C5
n10:Water-Solubility
n13:271B5980-363D-11E5-9242-09173F13E4C5 n13:271B5968-363D-11E5-9242-09173F13E4C5
n10:logP
n13:271B5966-363D-11E5-9242-09173F13E4C5 n13:271B5982-363D-11E5-9242-09173F13E4C5 n13:271B5969-363D-11E5-9242-09173F13E4C5
n10:logS
n13:271B5967-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:S01HA02 n12:D04AB03
n10:H-Bond-Acceptor-Count
n13:271B5976-363D-11E5-9242-09173F13E4C5
n10:H-Bond-Donor-Count
n13:271B5977-363D-11E5-9242-09173F13E4C5
n10:InChIKey
n13:271B5971-363D-11E5-9242-09173F13E4C5
n10:Polar-Surface-Area--PSA-
n13:271B5972-363D-11E5-9242-09173F13E4C5
n10:Polarizability
n13:271B5974-363D-11E5-9242-09173F13E4C5
n10:Refractivity
n13:271B5973-363D-11E5-9242-09173F13E4C5
n10:Rotatable-Bond-Count
n13:271B5975-363D-11E5-9242-09173F13E4C5
n10:affectedOrganism
Humans and other mammals
n10:casRegistryNumber
99-43-4
n10:category
n10:containedIn
n15:271B5965-363D-11E5-9242-09173F13E4C5
n10:Bioavailability
n13:271B597C-363D-11E5-9242-09173F13E4C5
n10:Ghose-Filter
n13:271B597E-363D-11E5-9242-09173F13E4C5
n10:MDDR-Like-Rule
n13:271B597F-363D-11E5-9242-09173F13E4C5
n10:Melting-Point
n13:271B5981-363D-11E5-9242-09173F13E4C5
n10:Number-of-Rings
n13:271B597B-363D-11E5-9242-09173F13E4C5
n10:Physiological-Charge
n13:271B597A-363D-11E5-9242-09173F13E4C5
n10:Rule-of-Five
n13:271B597D-363D-11E5-9242-09173F13E4C5
n10:Traditional-IUPAC-Name
n13:271B596B-363D-11E5-9242-09173F13E4C5
n10:pKa--strongest-acidic-
n13:271B5978-363D-11E5-9242-09173F13E4C5
n10:pKa--strongest-basic-
n13:271B5979-363D-11E5-9242-09173F13E4C5